

07 Feb 2017 | News

Number To Know...10

by

10 minutes is the time it takes to prep the non-surgical, ingestible Elipse gastric balloon for obesity treatment. Elipse is developed by Allurion Technologies, which just bagged \$19m in new funding.

10 minutes is all it takes to fill Allurion Technologies' Elipse gastric balloon with fluid as part of an in-office, non-surgical treatment for obesity. The balloon is delivered as a capsule attached to a catheter; the patient swallows the capsule and it degrades in the stomach. The balloon is then filled with 550ml of fluid via the catheter, after which the catheter is removed through the mouth. Allurion raised \$19m in January in a private equity round involving 45 investors. It is planning to raise up to \$27m in total. Elipse was CE marked in December 2015.

To read *Medtech Insight's* article on advances in minimally invasive obesity management technologies, click [here](#).

Meddevicetracker subscribers can access a profile of [Allurion Technologies](#) and a clinical trial analysis of [Elipse](#). Not a *Meddevicetracker* subscriber, [click here to request your free demo](#).